1. Introduction {#s0005}
===============

Persistent depressive symptoms in mid- and late-life contribute to poor psychosocial functioning, worsened medical comorbidities, and increased all-cause mortality and suicide ([@bb0025]). Treatment with selective serotonin reuptake inhibitors (SSRIs) or serotonin-norepinephrine reuptake inhibitors (SNRI) lead to remission in less than half of patients with depression ([@bb0280]; [@bb0285]). In case of non-response, augmentation strategies are only effective in 20--44% of cases ([@bb0130]; [@bb0180]; [@bb0270]). Thus, there is a need for novel pharmacologic strategies for treatment-resistant depression (TRD) that are safe, well-tolerated, and have a rapid onset of clinical benefit.

In this context, low-dose buprenorphine has emerged as a promising augmentation agent. It has an established safety profile (e.g., limited addiction risk, low risk of respiratory suppression, and pharmacokinetics not influenced by renal dysfunction) ([@bb0145]). Our pilot data also suggest that it is well-tolerated, has a rapid clinical effect, and may be effective in mid- and late-life adults with TRD ([@bb0145]). These pilot data have been corroborated by a recent randomized double-blind placebo-controlled trial of buprenorphine (combined with samidorphan) in younger adults ([@bb0085]).

Buprenorphine is a partial agonist at the mu opiate receptor (MOR) and antagonist at the kappa opiate receptor (KOR), though this affinity is complex ([@bb0080]; [@bb0260]). Cortical and limbic regions rich in opioid receptors are associated with emotional dysregulation and with clinical response to antidepressant pharmacotherapy ([@bb0190]). However, the specific brain circuits involved in these effects, and the mechanism of action of buprenorphine in treatment-resistant depression are still unknown. Given the complexity of the opioid receptors in buprenorphine and the overlapping distribution of different opioid receptors in the brain ([@bb0235]), we decided to explore the down-stream changes in emotional processing and reward circuitry as these are two characteristically dysfunctional neural systems in major depressive disorder ([@bb0165]). Therefore, we investigated: (1) low-dose buprenorphine\'s effect on emotional processing, (2) its effects on neural reward circuitry, and (3) whether acute changes predicted overall changes in depression severity. Our previous work ([@bb0135]; [@bb0140]) has shown that acute neural changes are associated with treatment response and may guide early clinical decisions. Measuring acute change in brain activity may inform which neural targets should be engaged in efforts to hasten treatment response.

A recently completed multi-site intervention development trial ([clinicaltrials.gov](http://clinicaltrials.gov){#ir0005} Identifier [NCT02176291](NCT02176291){#ir0010}) will help determine clinical efficacy of antidepressant augmentation with low-dose buprenorphine. The goal for this report is focused on describing neural target engagement that may be modulated by the drug. We employed two fMRI behavioral tasks (an emotional reactivity task ([@bb0110]) and a gambling task ([@bb0060])) during an 8-week clinical trial of low-dose buprenorphine or matching placebo augmentation in mid- and late-life adults with TRD. These two tasks probe the brain activity in the limbic and reward systems, respectively ([@bb0190]). We assessed whether acute activation changes in the limbic and reward systems were associated with improvement in depressive symptoms, evaluated by both the total score and the dysphoria subscale ([@bb0225]) from the Montgomery Asberg Depression Rating Scale ([@bb0205]). We explored dysphoria as we aimed to investigate the core antidepressant effect of buprenorphine and because it has been associated with KOR/dynorphin system in animals ([@bb0170]) and humans ([@bb0250]). Thus, the KOR/dynorphine system is a possible mechanism underlying buprenorphine\'s antidepressant effect. We defined early symptom improvement, henceforth "acute," as following 3 weeks of treatment, as there exists literature that suggests that clinical response within 2--4 weeks of treatment is predictive of remission ([@bb0010]; [@bb0125]). Thus, we expected a significant neural change by 3 weeks after initiation of treatment.

We expected that buprenorphine may alter limbic neural activation during the emotion reactivity task. Improvement of depressive symptoms may be associated with either an increased neural activation associated with improvement in emotion context insensitivity ([@bb0265]) or decreased neural activation associated with lower cognitive bias toward negative stimuli ([@bb0070]). Because of the low-doses in this study and reduced addictive profile of low-dose buprenorphine, we did not predict differences in reward network activation between those exposed to buprenorphine and placebo ([@bb0155]; [@bb0300]). However, increase in reward network activation was anticipated in those who improved clinically, irrespective of the buprenorphine or placebo groups.

2. Methods {#s0010}
==========

2.1. Participants and study design {#s0015}
----------------------------------

Participants were at least 50 years old and met DSM-IV criteria for major depressive disorder (MDD) with a minimum Montgomery-Åsberg Depression Rating Scale \[MADRS\] ≥ 15 ([@bb0205]). Participants were excluded if they had a major neurocognitive disorder (e.g., dementia), psychosis, bipolar disorder, substance or alcohol use disorder, or contraindications to MRI. We also excluded those with chronic pain, because we were interested in buprenorphine\'s antidepressant effect without contribution from its analgesic effect. The Institutional Review Board at the University of Pittsburgh approved the study, and all participants provided written informed consent.

This study consisted of two phases and was part of a multi-site intervention development trial investigating antidepressant augmentation with buprenorphine. The data reported here are from the Pittsburgh site, which also collected fMRI data during the augmentation phase.

During the first 12-weeks, participants with depression were treated openly with venlafaxine XR (up to 300 mg/day). Non-responders were randomized under double blind conditions to augmentation with either sublingual buprenorphine or matching placebo (2:1 allocation) for an additional 8 weeks. Buprenorphine or placebo was started at 0.2 mg/day and increased by 0.2 mg/day each week based on depression severity and tolerability up to a maximum of 1.2 mg/day. These dosages were based on previous open-label trials using buprenorphine for treatment resistant depression in younger (0.15--1.8 mg/day) and older adults (0.2--1.6 mg/day) ([@bb0030]; [@bb0145]). Participants had two fMRI scans: pre-randomization and after three weeks of exposure to buprenorphine/placebo, to explore the association between acute changes in activation and 8-week treatment response ([@bb0150]).

2.2. Assessments {#s0020}
----------------

The MADRS was administered weekly by raters blind to treatment assignment. Response was defined as a MADRS ≤10 for two consecutive weeks. We chose this definition of response (instead of 50% improvement from baseline) to include individuals in phase 2 who may have responded to venlafaxine, but were still quite symptomatic. To detect a depression-specific effect, all analyses also used the five-item dysphoria subscale of the MADRS comprising apparent sadness, reported sadness, lassitude, reduced concentration, and inability to feel ([@bb0225]).

Side effects were assessed weekly with the self-reported Antidepressant Side-Effect Checklist (ASEC) ([@bb0305]). Euphoria was assessed with a 0--10 visual analog scale ([@bb0160]) to identify a euphoric effect that may promote addictive behavior ([@bb0045]).

2.3. Emotional reactivity: face/shapes task ([@bb0105]) {#s0025}
-------------------------------------------------------

During the emotional reactivity task participants either matched faces or shapes. They were instructed to respond with an MR-compatible glove (left or right index finger) by identifying one of two images in the lower row that matches a "cue image" presented in the top row. Only negative emotional faces (angry or fearful) were shown; shapes were geometric forms. There were five shape-matching blocks (24 s) interleaved with four face-matching blocks. For the faces block, six images (balanced by sex and emotion \[angry or fearful\]) were presented. Before each block, participants were visually instructed to either "match emotion" or "match form" (2 s). Through this implicit emotional reactivity manipulation, the amygdala, anterior insula (aINS), rostral cingulate, and other associated areas are activated ([@bb0090]; [@bb0105]), which may serve as a proxy of brain changes in limbic circuitry during early treatment. Faces were presented from a set of 12 different images and are derived from a standard set of pictures of facial affect. We used E-Prime to present stimuli and record responses (Psychology Software Tools, Inc., Pittsburgh, PA. 2002). While this task does not have happy or neutral faces, the goal was to understand limbic reactivity (amygdala activation), as well as the regulatory components involved, which has been demonstrated best via angry and fearful faces ([@bb0115]). Notably, happy faces do not elicit a similar limbic response and those with depression can subjectively perceive neutral faces as more negative -- thus shapes instead of neutral faces are a good visual and motor control.

2.4. Reward: gambling task {#s0030}
--------------------------

This task ([@bb0060]) activates striatal and other reward-related brain regions ([@bb0065]; [@bb0315]). In this card-guessing game, a question mark appears on the screen as a cue. Participants guess whether the number of the hidden card is greater or lower than 5. Then the actual number is revealed, followed by an upward green, red, or yellow arrow for correct, incorrect, or tie guesses. Participants are told they will receive \$1.00 on a win trial and lose \$0.50 on a loss trial and that the hidden numbers are generated randomly from 1 to 9. Classic decision-making literature suggests that the impact of negative outcomes, such as losses, is larger than that of positive outcomes, such as gains; thus similar to past studies we have chosen a 2:1 win to loss ratio ([@bb0295]). In reality, the hidden numbers are picked by the computer based on the number chosen by the participant to fulfill a pre-determined sequence of win, loss, or neutral trials. A total of two blocks were run (38 s), with each consisting of 9 trials (3 of each trial). By comparing the activation for buprenorphine or placebo, this task probes the reward effect of buprenorphine (e.g., abuse potential).

2.5. Image acquisition {#s0035}
----------------------

All scanning was done on a 3 Tesla Trio TIM MRI scanner (Siemens, Berlin, Germany) using a 12-channel custom head coil located at the MR Research Center at the University of Pittsburgh. Magnetization-prepared rapid gradient-echo (MPRAGE), fluid attenuated inversion recovery (FLAIR), and T2\*-weighted blood‑oxygen level dependent (BOLD) sequences were collected during both tasks. Detailed parameters are described in the Supplementary Methods section (*Image Acquisition*). Participants also had a resting state BOLD scan, however this was not analyzed but will be given special attention in future work.

2.6. Image preprocessing {#s0040}
------------------------

Image preprocessing was conducted via Statistical Parametric Mapping software (SPM12; <http://www.fil.ion.ucl.ac.uk/spm/software/spm12>/) as detailed in the Supplementary Methods section (*Image Preprocessing*). Briefly, functional scans were motion corrected, normalized to a standard anatomical space (using the structural scans), and then smoothed. FLAIR scans were used to automatically extract white matter hyperintensity (WMH) burden.

2.7. Modeling task activation {#s0045}
-----------------------------

For both tasks, we performed a mass-univariate regression that modeled the mean of the voxel-wise time series, the six motion parameters, and the onset and duration of the task (faces and shapes for the emotion reactivity task; win, loss, and neutral for the reward task) convolved with the canonical hemodynamic response function. The model used a series of temporal cosines to model low frequency noise (1/128 Hz) and an autoregressive \[AR(1)\] filter was used to model aliased biorhythms and unmodelled activity/noise. The primary contrast for the emotional reactivity task was emotional faces minus shapes; while for the reward task the contrast was reward minus loss (other possible contrasts, including reward minus neutral and loss minus neutral, were reported in the Supplement).

2.8. Biochemistry analytical methods {#s0050}
------------------------------------

Buprenorphine and metabolite ([@bb0035]) concentrations were determined in venous plasma collected at the time of the second MRI. Three of the metabolites (norbuprenorphine, buprenorphine-3-glucuronide, and norbuprenorphine-3-glucuronide) ([@bb0035]) are biologically active with equal or higher plasma levels than the parent drug ([@bb0185]). Thus, we measured the plasma level of buprenorphine and these three metabolites. Plasma was stored at −80 °C until analyzed. Concentrations of buprenorphine and the major metabolites were determined by liquid chromatography-mass spectrometry as described previously ([@bb0255]), except that an ABSciex 6500 mass spectrometer was used.

2.9. Statistical analysis {#s0055}
-------------------------

Demographic and psychometric data were analyzed using the Statistical Package for the Social Sciences version 19.0 (SPSS19.0). All data were expressed as mean and standard deviations (SD), and the significance level was set at 0.05. Treatment assignment had been unblinded at the time of statistical analysis.

We performed voxel-wise statistical analyses using statistical non-parametric mapping (SnPM13; <http://warwick.ac.uk/snpm>) ([@bb0215]) with permutation testing (10,000 permutations per analysis). To adjust for multiple comparisons, we controlled the cluster-wise (uncorrected cluster forming threshold at p \< .001) family-wise error (FWE) rate at 0.05. Due to the limited sample sizes and limited approaches available voxel-wise, we have used a difference-based analysis rather than other statistical approaches (e.g., mixed-effects modeling -- which would have required a significantly greater sample size and number of observations).

We now describe the analyses conducted for both tasks separately. After conducting an independent samples *t*-test on baseline imaging comparing the two groups (i.e., buprenorphine and placebo) to verify that there were no differences in activation at baseline, we created a difference image for each participant by subtracting the pre-treatment contrast map from the week 3 (acute post-treatment) contrast map. We performed an independent samples t-test on this difference image to examine changes in activation between the two treatment groups (buprenorphine and placebo).

We also conducted a set of analyses with respect to associations between changes in depression severity and neural activation. Considering the sample size, we did not expect that there would be significant changes in activation, however these associations would be an important step to determining the neural impact of buprenorphine and placebo. We examined the association between early changes (at three weeks compared to pre-treatment) in activation and changes in depression during the 8-week treatment trial, and its interaction with treatment group (i.e., to examine whether early neural changes predicted changes in depression severity and if this was dependent on treatment group). Relative changes in depression severity were calculated for both the total MADRS or its dysphoria subscale based on the score at week 8 minus baseline score, divided by baseline score. Since we had defined response as a 50% improvement in symptoms (see Assessments section), we decided to use a ratio rather than the difference as this was more clinically meaningful whereas the raw difference does not indicate whether this was a meaningful change (e.g., a decrease in raw score of 15 may seem like a lot of improvement, but given a pre-treatment score of 40 -- this would not be considered a strong response).

As a post-hoc analysis, we also extracted the activation (measured as the value of the contrast in those regions) within the significant clusters, to assess their association with the plasma levels of buprenorphine and its metabolites. Finally, in additional exploratory analyses, we investigated the association between baseline activation and baseline symptom severity or end-of-trial symptom improvement (supplement Table S3 and Figs. S2--3). Similarly, we investigated the association between euphoria and activation during the gambling task.

3. Results {#s0060}
==========

In the buprenorphine group, 3 participants exited the trial prematurely and only had baseline fMRI scans (due to non-compliance with the protocol, withdrawal of consent, and death from pre-existing cardiac disease unrelated to study participation); one was excluded due to corrupted imaging data; and one exited after only 6 weeks (due to high depression severity) but the data were included in the analysis carrying forward the last depression score. Thus, 16 participants randomized to buprenorphine and 11 randomized to placebo that completed two fMRIs are included in the analysis (Supplemental Fig. S1). These 27 participants did not significantly differ from the three who exited the study in terms of age, sex, or baseline depression severity.

3.1. Clinical measures {#s0065}
----------------------

In this multi-site treatment development project, the clinical data from the Pittsburgh site indicated no differences between the buprenorphine and placebo groups for any of the demographic (age, sex, ethnicity, education), baseline depression scores, or other clinical characteristics (Supplemental Table S1). The final mean (SD) buprenorphine dosage was 0.5 (0.2) mg/day. All participants showed some improvement in depression severity during the trial. There was no significant group (placebo vs. buprenorphine) difference in: improvement of depressive symptoms (with either the total MADRS or dysphoria subscale); side effects (ASEC); or euphoria (visual analog scale) (Supplemental Table S2). We further confirmed no significant differences between the two groups by performing a mixed-ANOVA using weekly MADRS, where we found that there was no significant interaction between group and time \[F(8,168) = 0.44, p = .898\], no significant group differences \[F(1,21) = 0.62, p = .439\], but there was a significant decrease in MADRS across time independent of group \[F(8,168) = 3.46, p \< .005\].

3.2. Emotional reactivity task: face/shapes {#s0070}
-------------------------------------------

We found no group differences in activation at baseline or in the change in activation but found that there existed significant associations between neural changes and symptom changes. Specifically, we found that independent of group, an increase in rostral anterior cingulate gyrus (rACC)/ventral medial prefrontal gyrus (vmPFC) activation was associated with overall improvement on both total MADRS and dysphoria subscale ([Table 1](#t0005){ref-type="table"} and [Fig. 1](#f0005){ref-type="fig"}a/b). In the buprenorphine, but not the placebo group, an increase in left anterior insula (aINS) and bilateral middle frontal gyrus (MFG) activation was associated with improvement on the dysphoria subscale ([Table 1](#t0005){ref-type="table"} and [Fig. 2](#f0010){ref-type="fig"}). Changes in these regions were not associated with levels of BPN or its metabolites ([Table 2](#t0010){ref-type="table"}).Table 1Association between changes in fMRI brain activity after three weeks and depressive symptom improvement.Table 1RegionBAMNI coordinatesCluster size[⁎](#tf0005){ref-type="table-fn"}Peak txyzEmotional reactivity taskMADRS total score in all participants rACC/vmPFC32,24−23265884.9Dysphoria subscale in all participants rACC/vmPFC32,10,242642−222595.5 Left MFG/DLPFC10,9,46−38421016516.0Dysphoria subscale in buprenorphine group Left aINS, MFG10−364685525.3 Right MFG10225062084.7  Gambling taskMADRS total score in all participants Left cuneus19−6−8828239−5.0[^2][^3]Fig. 1Three-week increase in rACC/vmPFC activity in emotional reactivity task was associated with end-of-trial symptom improvement across all subjects. 2a. Association with MADRS improvement. 2b. Association with dysphoria improvement.Fig. 1Fig. 2Three-week increase in left anterior insula and bilateral middle frontal gyrus activity in emotional reactivity task was associated with end-of-trial dysphoria improvement in buprenorphine, not in placebo. Note: Even after excluding the two participants in the BPN group that may seem like outliers (far two most points), the association still holds \[r(13) = 0.84\].Fig. 2Table 2The correlation of three-week drug level, three-week brain activity increase in fMRI task, end-of-trial symptom improvement, and within different metabolites.Table 2BPNnorBPNB3GN3GPearson correlation (p-value) Brain activity within the cluster from regression analysis aINS/bilateral MFC in face/shapes task0.007(0.981)0.094(0.739)0.131(0.642)*0.509(0.053)* ACC/vmPFC in face/shapes task (with MADRS)−0.052(0.853)0.042(0.882)0.053(0.852)0.425(0.114) ACC/vmPFC in face/shapes task (with dysphoria)−0.090(0.749)−0.114(0.687)0.094(0.739)0.305(0.269) Occipital cluster in gambling task0.043(0.878)0.322(0.242)0.029(0.917)−0.289(0.296) Symptom improvement MADRS (%)0.107(0.704)−0.153(0.586)0.357(0.191)0.381(0.162) dysphoria subscale (%)0.166(0.553)0.031(0.913)0.18(0.180)*0.442(0.099)* Inter-metabolite association Buprenorphine (BPN)--**0.694(0.004)0.734(0.002)***0.456(0.087)* Norbuprenorphine (norBPN)--*0.460(0.085)0.45(0.092)* Buprenorphine-3-Glucuronide (B3G)--**0.651(0.009)** Norbuprenorphine-3-Glucuronide (N3G)--[^4]

3.3. Gambling task {#s0075}
------------------

We found no group differences in activation at baseline or in the change in activation, but again found significant associations between neural and symptom changes. An acute increase in visual cortex activation was associated with improvement in total MADRS ([Table 1](#t0005){ref-type="table"} and [Fig. 3](#f0015){ref-type="fig"}). However, no group specific associations were detected, even under different contrasts, including reward minus neutral and loss minus neutral (supplemental Fig. S4). Changes in these regions were not associated with levels of BPN or its metabolites ([Table 2](#t0010){ref-type="table"}).Fig. 3Three-week decrease in visual cortex activity in gambling task was associated with MADRS improvement across all subjects.Fig. 3

4. Discussion {#s0080}
=============

We identified associations between increased emotion reactivity rACC/vmPFC activation and improvement of depressive symptoms independent of treatment (placebo or buprenorphine) and also between increased emotion reactivity left aINS and bilateral MFG activation and improvement of dysphoria in the buprenorphine but not placebo groups. Given the preliminary nature of these results, it is important to replicate this study and validate these results especially given the modest sample size and failure to identify significant changes in neural activation. However, given that this is one of the first studies on buprenorphine in late-life depression, we propose that these results may be related to some existing literature and provide a more general discussion to help identify future work.

During the emotional reactivity task, we observed that an increase in rACC/vmPFC activation was associated with an improvement in depressive symptoms, regardless of the intervention. The increase in rACC/vmPFC activation may reflect top-down control of limbic systems by rACC ([@bb0075]) and vmPFC ([@bb0210]). Our finding in the rACC is consistent with the previously reported association in a PET study between increased glucose metabolism of rACC and response to both fluoxetine and placebo ([@bb0195]). Similarly, rACC activity has been associated with placebo analgesia ([@bb0020]; [@bb0240]), and modulation of endogenous μ-opioid receptors has been linked to placebo response in pain and antidepressant treatment ([@bb0230]; [@bb0320]). Within the ACC, both MOR binding ([@bb0230]) and its resting-state functional connectivity ([@bb0275]) correlated with placebo response and predicted subsequent antidepressant response. Since the ACC is densely populated with both MOR and KOR ([@bb0120]), it is possible that buprenorphine and placebo modulate the opioid system in rACC to improve depressive symptoms.

Increased activation in left aINS and bilateral MFG was associated with improvement on the dysphoria subscale for the buprenorphine but not the placebo group. Both aINS and MFG are associated with negative facial emotional processing ([@bb0095]), and activation of the aINS has been implicated in the response to antidepressant treatments ([@bb0050]; [@bb0175]; [@bb0200]). Consistent with our findings, Davidson et al. reported increasing left aINS activation during a negative affect processing fMRI task with successful venlafaxine treatment ([@bb0050]). The aINS functions as a hub in sensing or prioritizing emotional and cognitive salience ([@bb0040]), and successful emotional regulation presumably requires improvement in awareness and differentiation of one\'s own emotions ([@bb0015]). Thus, our results suggest that the combined effect from the heightened emotional awareness and greater implicit emotional regulation among participants exposed to low-dose buprenorphine ([@bb0100]; [@bb0220]; [@bb0245]) may be associated with improvement in depression.

It is of interest in our study that the MADRS dysphoria subscale was more sensitive than the overall MADRS scale in suggesting an antidepressant effect of low-dose buprenorphine augmentation. This is supported by a recent PET study using a KOR-selective ligand in trauma patients ([@bb0250]). In that study, it was observed that activating the dynorphine/KOR system in the aINS induced dysphoria. Given that we did not find significant changes in activation, but rather associations between changes in activation and changes in depression/dysphoria severity, it is critical to replicate this exploratory finding to validate these results. Ultimately, we were limited by the number of scans at baseline and 3 weeks after beginning treatment, as it is likely that similar neural engagement could be detected in post-treatment with an association beyond the dysphoria subscale as it could take a longer duration for other items in MADRS to improve during depression treatment ([@bb0005]; [@bb0290]; [@bb0310]).

Although there existed an association between the early increase in cuneus activation during the reward task and symptom improvement across all participants, no expected brain areas involved in reward activation, including ventral striatum, caudate, or insula ([@bb0055]), were found to be related to symptom improvement. If this lack of greater engagement of the reward system with low-dose buprenorphine compared to placebo is replicated, it may support limited activation of neural reward circuits. However considering the modest sample size, it is unclear if this is just an effect size that we were unable to detect.

We acknowledge that the small sample size does not permit meaningful inferences about clinical effect. We observed neither significant differences between placebo and buprenorphine clinically nor significant neural changes following three weeks of treatment. We did observe that acute changes in activation was associated with changes in depression severity for individuals who received buprenorphine but not placebo. These preliminary associations help improve our understanding of the neural mechanisms of buprenorphine and placebo treatment and requires further investigation. It should be noted however, that only a limited set of regions were associated with buprenorphine specific changes in depression severity. The non-significance of the association in the placebo group may also have to do with the sample size, however the effect size was small (r = −0.16). In addition to the modest sample size, the low dose of buprenorphine may also have reduced our power to detect significant changes or associations. Finally, our analyses did not allow for causative inference; thus, all results are correlational in nature and do not imply causation. Future studies should include multiple assessment points throughout the study to sample fMRI and clinical measures to understand the causative nature of these changes. Further validation of these findings is needed in a sample that includes both clinically significant differences in depression severity and neural activation.

Although speculative, it is possible that we would have observed greater separation from placebo for both antidepressant clinical effect and neural activation with a higher dosage of buprenorphine. For example, in a recent placebo controlled study in which the active treatment was superior to placebo, buprenorphine (combined with samidorphan, a potent MOR antagonist) was prescribed at 2--4 mg/day ([@bb0085]). While this is the first study investigating the engagement of depression-relevant neural targets, higher dosages should be considered in future translational studies of buprenorphine.

5. Conclusion {#s0085}
=============

This study found that acute changes in neural activation were associated with changes in symptom improvement in dysphoria in mid- and lafe-life adults with TRD treated with low-dose buprenorphine augmentation. Changes in specific neural activation in the buprenorphine but not the placebo group predicted symptom improvement at 8 weeks. Specifically, this associated increase in left anterior insula and bilateral middle frontal gyrus activation during an emotional reactivity task may explain a unique mechanism of augmentation with this opioid agent. Task-based fMRI may provide a sensitive tool to optimize the dosage of buprenorphine in future studies, balancing the trade-off between clinical efficacy and abuse risk. Future studies are needed to confirm the specific changes we observed in neural activation and to guide dose-finding strategies.
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